Keywords: bextra, trial, terminated, interim, data, survival, advantage

Bextra trial terminated on interim data, no survival advantage

Article | 03 August 1999

A Phase III trial of Interneuron Pharmaceuticals and IncaraPharmaceuticals' Bextra (bucindolol HCl) in heart failure has been terminated early by ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck

Merck KGaA

Go to company listing

Related Drugs

Bextra

Valdecoxib

Redux

Dexfenfluramine

Go to drug listing